Renal Denervation in Patients With Refractory Hypertension

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00753285

Enrollment

Registered

2008-09-16

Start date

2008-09-30

Completion date

2013-05-31

Last updated

2014-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Brief summary

The purpose of this study is to investigate the clinical utility of renal denervation for the treatment of refractory hypertension.

Interventions

DEVICERenal Denervation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Systolic blood pressure of 160 mmHg or greater * On 3 or more antihypertensive medications * eGFR \>= 45 mL/min

Exclusion criteria

* Renal artery abnormalities * Known secondary hypertension attributable to a cause other than sleep apnea * MI, angina, CVA within 6 months * Type 1 diabetes * Others

Design outcomes

Primary

Measure	Time frame
Safety - complications associated with delivery and/or use of the Ardian Catheter, adverse renal events, electrolyte disturbances, hemodynamic events.	Through 3 years

Secondary

Measure	Time frame
Physiologic response to renal denervation (e.g., blood pressure reduction)	Through 3 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 22, 2026